GT Biopharma (GTBP) Long-Term Debt Issuances (2011 - 2021)

GT Biopharma (GTBP) has reported Long-Term Debt Issuances for 9 consecutive years, with $1.2 million the latest figure, recorded in Q1 2021.

• In Q1 2021, Long-Term Debt Issuances rose 502.5% year-over-year to $1.2 million; the TTM figure through Dec 2021 stood at $1.2 million (changed N/A YoY), while the FY2021 annual figure was $1.2 million, changed N/A from the prior year.
• Long-Term Debt Issuances grew to $1.2 million in Q1 2021 per GTBP's latest filing, from -$5.7 million in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $8.0 million in Q3 2018 and bottomed at -$5.7 million in Q4 2020.
• Historically, Long-Term Debt Issuances has averaged $1.8 million across 5 years, with a median of $1.1 million in 2019.
• Annual changes were most pronounced in 2019 — Long-Term Debt Issuances surged 3327.0% — and 2020, when it plunged 265.07%.
• GT Biopharma's Long-Term Debt Issuances stood at $6.0 million in 2017, then sank by 98.33% to $100000.0 in 2018, then soared by 3327.0% to $3.4 million in 2019, then slumped by 265.07% to -$5.7 million in 2020, then surged by 121.3% to $1.2 million in 2021.
• Business Quant data shows GTBP's Long-Term Debt Issuances at $1.2 million in Q1 2021, -$5.7 million in Q4 2020, and $1.2 million in Q3 2020.